Related Experiment Video
Updated: Mar 15, 2026
05:58
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
Published on: June 25, 2019
8.0K
Basal Insulin Use With GLP-1 Receptor Agonists
Sarah L Anderson1, Jennifer M Trujillo1
1University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO.
Summary
Combining basal insulin with a glucagon-like peptide 1 receptor agonist offers improved glycemic control for type 2 diabetes patients. This combination presents a safe, effective, and less burdensome alternative to basal-bolus insulin therapy.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Basal insulin and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are key therapies for type 2 diabetes.
- Combining these agents offers synergistic benefits for glycemic management.
- Current treatment paradigms are evolving towards more effective and convenient options.
Purpose of the Study:
- To review the rationale for combining basal insulin and GLP-1 RAs.
- To summarize the clinical evidence supporting this combination therapy.
- To discuss the implications for type 2 diabetes management.
Main Methods:
- Literature review of clinical studies and trials.
- Analysis of data on glycemic control, hypoglycemia, and weight.
- Examination of fixed-ratio combination product development.
Main Results:
- Combination therapy demonstrates superior glycemic control compared to basal insulin alone.
- Low risk of hypoglycemia and significant weight reduction observed.
- Fixed-ratio products offer enhanced convenience and adherence.
Conclusions:
- The combination of basal insulin and GLP-1 RAs is a highly effective treatment strategy for type 2 diabetes.
- This approach provides significant clinical benefits with a favorable safety profile.
- Future advancements include single-injection fixed-ratio products, improving patient treatment burden.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.2K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.2K
01:06Oral Hypoglycemic Agents: Glinides
821
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
821
01:23Dipeptidyl Peptidase 4 Inhibitors
876
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
876
01:16Insulin: Dosing Regimen and Adverse Effects
1.0K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.0K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
813
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
813
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
753
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
753